RE:RE:Add Biomedical products used in hospitals in AsiaWhen acquiring a private company, revenue, yes, ebitda, rarely if ever is shared or available. The reason is that share distribution and quantity, associated with a private company are less structured (as regulated within a public company) and of little consequence. Unfortunately in these types of acquisitions, even when revenue is mentioned, all that is left for shareholders is a level of trust in the DD carried out by the acquiring company; that and subsequent NRs. ScreenPro made no explicit mention of this being a pre-revenue company. In fact if they were at fault for anything it was that they didnt mention much. Add Biomedical is working on full commercialization of its products in North America. Does that imply what you have expressed or does it suggest that they had a market elsewhere? Its not unusual for a research company to be limited in commercialization by a lack of business acumen and access to capital. Add Biomedical is financially secure with over $1,000,000 in cash to help its operations. Yes, it would be nice to know the source of this money ....but this kind of information is rarely shared with investors in this context. I would like to think Lena has taken ScreenPro well past the days of significantly misleading correspondence (NRs) and suspect moves. In spite of some hiccups she appears to be successfully maneuvering a company with solid revenues within its current niche to a company with longterm growth and expansion. Time will tell! Cheers!!!
lscfa wrote: Normally co.s disclose if the target acquisition has revenues and ebitda so shareholders can determine if co. is overpaying. ScreenPro made us think it was buying a pre-revenue co.